Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues

Nuclear Medicine and Biology

Volumn 37, Issue 2, 2010, Pages 167-178

  Wilbur, D Scott ^a   Chyan, Ming Kuan ^a   Hamlin, Donald K ^a   Perry, Matthew A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

closo Decaborate(2 ); Radioiodination; Radiolabeling; Tissue retention

Indexed keywords

ASTATINE 211; CARBOXYLIC ACID; CLOSO DECABORATE DERIVATIVE; FUNCTIONAL GROUP; HYDRAZONE DERIVATIVE; IODINE 125; IODINE 131; RADIOISOTOPE; SODIUM IODIDE I 125; SODIUM IODIDE I 131; TOSYLCHLORAMIDE SODIUM; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOIODINATION; TISSUE DISTRIBUTION;

ANIMALS; BORATES; BORON COMPOUNDS; HALOGENATION; INJECTIONS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE;

EID: 76949084254     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.10.004     Document Type: Article

References (42)

1. Lucignani G. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213. Eur J Nucl Med Mol Imaging 35 (2008) 1729-1733
2. 211At-labeled monoclonal antibodies. Nucl Med Biol 34 (2007) 779-785
3. Mulford D.A., Scheinberg D.A., and Jurcic J.G. The promise of targeted alpha-particle therapy. J Nucl Med 46 Suppl 1 (2005) 199S-204S
4. Couturier O., Supiot S., Degraef-Mougin M., Faivre-Chauvet A., Carlier T., Chatal J.F., et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 32 (2005) 601-614
5. Imam S.K. Advancements in cancer therapy with alpha-emitters: a review. Int J Rad Oncol Biol Phys 51 (2001) 271-278
6. Brechbiel M.W. Targeted alpha-therapy: past, present, future?. Dalton Trans (2007) 4918-4928
7. Wilbur D.S. Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug Chem 3 (1992) 433-470
8. Kabalka G.W., and Varma R.S. The synthesis of radiolabeled compounds via organometallic intermediates. Tetrahedron 45 (1989) 6601-6621
9. Moerlein S.M. Regiospecific incorporation of no-carrier-added radiobromine and radioiodine into aromatic rings via halogenodegermylation. J Chem Soc Perkin Trans I (1985) 1687-1692
10. 211At]astatide and development of labeling reagents to increase stability. Curr Radiopharm 1 (2008) 144-176
11. Wilbur D.S., Chyan M.K., Hamlin D.K., Vessella R.L., Wedge T.J., and Hawthorne M.F. Reagents for astatination of biomolecules: 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconjug Chem 18 (2007) 1226-1240
12. Wilbur D.S., Chyan M.K., Hamlin D.K., Kegley B.B., Risler R., Pathare P.M., et al. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconjug Chem 15 (2004) 203-223
13. Wilbur D.S., Hamlin D.K., Chyan M.K., Kegley B.B., Quinn J., and Vessella R.L. Biotin reagents in antibody pretargeting: 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives. Bioconjug Chem 15 (2004) 601-616
14. Wilbur D.S., Hamlin D.K., Srivastava R.R., and Chyan M.K. Synthesis, radioiodination, and biodistribution of some nido- and closo-monocarbon carborane derivatives. Nucl Med Biol 31 (2004) 523-530
15. Press O.W., Shan D., Howell-Clark J., Eary J., Appelbaum F.R., Matthews D., et al. Comparative metabolism and retention of iodine-125, yttrium-90, indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56 (1996) 2123-2129
16. Duncan J.R., and Welch M.J. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 34 (1993) 1728-1738
17. Stein R., Goldenberg D.M., Thorpe S.R., Basu A., and Mattes M.J. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 55 (1995) 3132-3139
18. Hawthorne M.F., and Maderna A. Applications of radiolabeled boron clusters to the diagnosis and treatment of cancer. Chem Rev 99 (1999) 3421-3434
19. Soloway A.H., Tjarks W., Barnum B.A., Rong F.G., Barth R.F., Codogni I.M., et al. The chemistry of neutron capture therapy. Chem Rev 98 (1998) 1515-1562
20. Akizawa H., Uehara T., and Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev 60 (2008) 1319-1328
21. Akizawa H., and Arano Y. Altering pharmacokinetics of radiolabeled antibodies by the interposition of metabolizable linkages. Metabolizable linkers and pharmacokinetics of monoclonal antibodies. Q J Nucl Med 46 (2002) 206-223
22. Wilbur D.S., Chyan M.K., Hamlin D.K., and Perry M.A. Reagents for astatination of biomolecules: 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211. Bioconjug Chem 20 (2009) 591-602
23. Knoth W.H. Chemistry of boranes: XXXI. 1,10-Bis(hydroxymethyl)octachlorodecaborate (2-). J Am Chem Soc 89 (1967) 4850-4852
24. Kaplan H.M., Brewer N.R., and Blair W.H. Physiology. In: Foster H.L., Small J.D., and Fox J.G. (Eds). The Mouse in Biomedical Research (1983), Academic Press, New York 248-292
25. 2-. J Am Chem Soc 89 (1967) 4842-4850
26. -2. J Am Chem Soc 86 (1964) 3973-3983
27. Nakamae H., Wilbur D.S., Hamlin D.K., Thakar M.S., Santos E.B., Fisher D.R., et al. Biodistributions, myelosuppression and toxicities in mice treated with an anti-CD45 antibody labeled with the α-emitting radionuclides bismuth-213 or astatine-211. Cancer Res 69 (2009) 2408-2415
28. Paik C.H., Yokoyama K., Reynolds J.C., Quadri S.M., Min C.Y., Shin S.Y., et al. Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor. J Nucl Med 30 (1989) 1693-1701
29. 99mTc-radiolabeled antibody Fab′-chelator conjugate. Bioconjug Chem 1 (1990) 431-437
30. Arano Y., Matsushima H., Tagawa M., Koizumi M., Endo K., Konishi J., et al. A novel bifunctional metabolizable linker for the conjugation of antibodies with radionuclides. Bioconjug Chem 2 (1991) 71-76
31. Tibben J.G., Massuger L.F.A.G., Boerman O.C., Claessens R.A.M.J., Borm G.F., Pak K.Y., et al. Decreased kidney uptake of technetium-99m-labelled Fab′ fragments in ovarian carcinoma bearing nude mice using a cleavable chelator. Nucl Med Biol 21 (1994) 17-24
32. Meares C.F., McCall M.J., Deshpande S.V., DeNardo S.J., and Goodwin D.A. Chelate radiochemistry: cleavable linkers lead to altered levels of radioactivity in the liver. Int J Cancer 2 (1988) 99-102
33. Peterson J.J., and Meares C.F. Cathepsin substrates as cleavable peptide linkers in bioconjugates, selected from a fluorescence quench combinatorial library. Bioconjug Chem 9 (1998) 618-626
34. Kumaresan P.R., Natarajan A., Song A., Wang X., Liu R., DeNardo G., et al. Development of tissue plasminogen activator specific "on demand cleavable" (odc) linkers for radioimmunotherapy by screening one-bead-one-compound combinatorial peptide libraries. Bioconjug Chem 18 (2007) 175-182
35. West K.R., and Otto S. Reversible covalent chemistry in drug delivery. Curr Drug Discov Technol 2 (2005) 123-160
36. Ulbrich K., and Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev 56 (2004) 1023-1050
37. Kratz F., Beyer U., and Schutte M.T. Drug-polymer conjugates containing acid cleavable bonds. Crit Rev Ther Drug Carrier Syst 16 (1999) 245-288
38. Lapeyre M., Leprince J., Massonneau M., Oulyadi H., Renard P.Y., Romieu A., et al. Aryldithioethyloxycarbonyl (Ardec): a new family of amine protecting groups removable under mild reducing conditions and their applications to peptide synthesis. Chemistry 12 (2006) 3655-3671
39. 131I-labelled m-iodohippuric acid and its behaviour in kidney function studies compared to o-iodohippuric acid. Int J Appl Radiat Isot 24 (1973) 463-469
40. De Duve C., De Barsy T., Polle B., Trouet A., Tulkens P., and Van Hoof F. Lysosomotropic agents. Biochem Pharm 23 (1974) 2495-2531
41. Mueller B.M., Wrasidlo W.A., and Reisfeld R.A. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjug Chem 1 (1990) 325-330
42. Kaneko T., Willner D., Monkovic I., Knipe J.O., Braslawsky G.R., Greenfield R.S., et al. New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity. Bioconjug Chem 2 (1991) 133-141